Top Reasons to Read this Phase One Clinical Trials Report
Control critical cost drivers: Total trial costs increase with protocol complexity. Manage key cost-drivers, including number of patients, patient visits, trial duration and specialty trial requirements. Examine benchmarks detailing total trial costs, per-patient costs and per-patient visit costs across 10 key therapeutic areas, including oncology and central nervous system.
Boost phase one clinical trials planning to prevent delays — and propel teams toward trial completion Set defined milestones and explore phase one clinical trials duration data for each stage of the process, and draw on executives’ strategies for keeping ahead of schedule.
Right-size your clinical team and improve vendor management: Balance in-house and vendor capabilities to increase patient recruitment, and analyze staffing metrics, including sponsor headcounts, for 25 Phase one clinical trials across therapeutic areas. Lastly, follow strategic recommendations for vendor selection and management.
Key Questions that are Answered About Phase 1 Clinical Trials
- Where are Phase I teams positioned? How many FTEs make up Phase I teams?
- How do teams work with other internal resources to select compounds for testing?
- How do teams determine Phase I budgets? What factors impact final costs? How do trial costs compare across therapeutic areas?
- How long do Phase I clinical trials last? How much does clinical trials’ actual duration deviate from planned trial duration? What factors cause Phase I trial delays? How can teams avoid delays?
- How do Phase I teams use outsourcing? How do teams choose their vendors? What are best practices for vendor management?
|Publication Date||January 2013|
|Charts / Graphics||70 +|